Analyzing Harmony Biosciences (NASDAQ:HRMY) & Vitro Diagnostics (OTCMKTS:VODG)

Harmony Biosciences (NASDAQ:HRMY) and Vitro Diagnostics (OTCMKTS:VODG) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, analyst recommendations and risk.

Valuation & Earnings

This table compares Harmony Biosciences and Vitro Diagnostics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$868.45 million	2.34	$158.69 million	$2.48	14.14
Vitro Diagnostics	$2.06 million	N/A	-$10.85 million	($2.21)	-0.18

Harmony Biosciences has higher revenue and earnings than Vitro Diagnostics. Vitro Diagnostics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

86.2% of Harmony Biosciences shares are held by institutional investors. 11.0% of Harmony Biosciences shares are held by insiders. Comparatively, 27.7% of Vitro Diagnostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Harmony Biosciences and Vitro Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	16.20%	17.19%	11.99%
Vitro Diagnostics	-444.35%	N/A	-195.51%

Analyst Recommendations

This is a summary of recent recommendations for Harmony Biosciences and Vitro Diagnostics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1	6	4	0	2.27
Vitro Diagnostics	0	0	0	0	0.00

Harmony Biosciences presently has a consensus price target of $40.89, indicating a potential upside of 16.59%. Given Harmony Biosciences’ stronger consensus rating and higher probable upside, equities analysts plainly believe Harmony Biosciences is more favorable than Vitro Diagnostics.

Summary

Harmony Biosciences beats Vitro Diagnostics on 11 of the 12 factors compared between the two stocks.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

About Vitro Diagnostics

Vitro Diagnostics, Inc., doing business as Vitro Biopharma, focuses on the development, manufacture, and distribution of stem cell products and related tools for use in research, drug discovery, and clinical trials in the United States. Its stem cell technology includes cell lines, supporting products, and methods for generation and differentiation of stem cells into products for the treatment of diseases, such as heart disease, arthritis, multiple sclerosis, brain injury, autism, stroke, Parkinson's, and Alzheimer's diseases. The company also offers Tools for Stem Cell and Drug Discovery that provide researchers basic tools needed to advance stem cell technology, including stem cells and their derivatives; media for growth and differentiation of stem cells; and tools for measurement of stem cell quality, potency, and response to toxic agents. In addition, it offers MSC-Gro, a cell culture media product; MSC cell line for the treatment of skeletal muscular conditions, such as tendonitis, ligament injury, osteoarthritis and accelerated bone fracture healing, etc.; and testing and therapies related to endogenous stem cell activation. Further, the company provides diagnostic testing of stem cell activation and determination of stem cell functional status; and cell-based assays for discovery of novel stem cell activation agents and drugs for the treatment of osteoporosis. Vitro Diagnostics, Inc. was founded in 1986 and is based in Golden, Colorado.